TRANSCODE THERAPEUTICS, INC. (RNAZ) Operating cash flow 2020–2025
TRANSCODE THERAPEUTICS, INC. (RNAZ) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$19.5MFY2025 · since FY2020: -$492,971 → -$19.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$19.5M | -46.3% |
| FY2024 | -$13.3M | +26.2% |
| FY2023 | -$18.1M | -14.7% |
| FY2022 | -$15.8M | -199.3% |
| FY2021 | -$5.3M | -968.4% |
| FY2020 | -$492,971 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAZ financial trends
RNAZ RevenueRNAZ Net incomeRNAZ Net marginRNAZ Gross profitRNAZ Gross marginRNAZ Operating incomeRNAZ Operating marginRNAZ Free cash flowRNAZ Capital expendituresRNAZ Return on equityRNAZ Stock buybacksRNAZ Dividends paidRNAZ Total assetsRNAZ Total liabilitiesRNAZ Shareholders’ equityRNAZ overview →